The PORTOLA Study: An Investigational Drug Trial for Autoimmune Hepatitis (AIH)

Clinical Trial Title

The PORTOLA Study: A Randomized, Phase 2a, Investigational Drug vs Placebo Study Evaluating the Safety and Efficacy of an Investigational Drug in Patients with Autoimmune Hepatitis (AIH)

National Clinical Trial Number:


Contact Information

Clinical Trial Protocol Description:

This is a study looking at how safe and how well a specific investigational drug works in patients with AIH who are not responding to standard of care treatment. This study is being conducted at the Rush University downtown campus so you must be willing to come to that location for research visits.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have a clinical diagnosis of AIH and signs of active disease despite standard-of-care therapy.
  • Are willing to use and taper glucocorticoid therapy.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a history of thyroiditis, celiac disease, or other autoimmune disorder known to be associated with transaminitis.
  • Have taken rituximab, other B- or T-cell depleting agents, or alkylating agents within 6 months of Screening, unless B- or T-cells have been shown to return to normal values.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Steven Flamm, MD

Contact Information

Diana Goldman

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more